Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.

Minor protease inhibitor mutations at baseline do not increase the risk for a virological failure in HIV-1 subtype B infected patients.

BACKGROUND: Minor protease inhibitor (PI) mutations often exist as polymorphisms in HIV-1 sequences from treatment-naïve patients. Previous studies showed that their presence impairs the antiretroviral treatment (ART) response. Evaluating these findings in a larger cohort is essential. METHODS: To s...

Full description

Bibliographic Details
Main Authors: Alexandra U Scherrer, Bruno Ledergerber, Viktor von Wyl, Jürg Böni, Sabine Yerly, Thomas Klimkait, Cristina Cellerai, Hansjakob Furrer, Alexandra Calmy, Matthias Cavassini, Luigia Elzi, Pietro L Vernazza, Enos Bernasconi, Huldrych F Günthard, Swiss HIV Cohort Study
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3377720?pdf=render

Internet

http://europepmc.org/articles/PMC3377720?pdf=render

Similar Items